Compare Repligen Corporation Common Stock (RGEN) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs ProShares Ultra Semiconductors — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while ProShares Ultra Semiconductors trades at $80.63 (market cap $2.80B). The key difference: Repligen Corporation Common Stock is far larger — about 4× ProShares Ultra Semiconductors's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and ProShares Ultra Semiconductors for 30 Days on average.
| RGEN | USD | |
|---|---|---|
Market Cap | $11.14B | $2.80B |
Volume | 1,259,263 | 467,963 |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.57 | $113.53 |
52-Week Low | $102.87 | $43.19 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
USD stock trades at $91.26 with a modest 0.26% daily gain, showing neutral momentum amid bearish technical signals. The company declared a $0.13 dividend for H2-2026, payable September 29, 2026. Technical indicators show mixed signals with moving averages bearish but oscillators neutral, while support sits at $90 and resistance at $93.
Fundamental data remains limited with key ratios unavailable, requiring deeper financial review. The stock faces headwinds from bearish technical trends but maintains dividend distribution. Investment appeal hinges on upcoming financial disclosures and market sentiment shifts amid current neutral oscillators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
